# CANDOR (NCT03158688)

> Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

No report yet. It can be ordered.

- Drugs tested: daratumumab plus carfilzomib
- Indication: relapsed or refractory multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03158688
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Amgen
- Conditions: Relapsed Multiple Myeloma; Refractory Multiple Myeloma
- Interventions: Dexamethasone; Daratumumab; Carfilzomib
- Enrollment: 466
- Primary outcome: Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only)

## Indexed commentary on CANDOR so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 70 posts on X
- 25 YouTube videos
- 13 podcast episodes

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=candor-nct03158688

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03158688", "email": "<work email>"}; the inbox owner confirms by the emailed link.